Q3 2024 Earnings Estimate for Krystal Biotech, Inc. Issued By William Blair (NASDAQ:KRYS)

Krystal Biotech, Inc. (NASDAQ:KRYS) – Investment analysts at William Blair increased their Q3 2024 earnings per share (EPS) estimates for shares of Krystal Biotech in a report issued on Monday, August 5th. William Blair analyst T. Lugo now expects that the company will post earnings per share of $0.89 for the quarter, up from their previous forecast of $0.63. The consensus estimate for Krystal Biotech’s current full-year earnings is $2.00 per share. William Blair also issued estimates for Krystal Biotech’s Q4 2024 earnings at $0.97 EPS and FY2024 earnings at $2.75 EPS.

Several other brokerages have also recently weighed in on KRYS. Stifel Nicolaus reaffirmed a “buy” rating and issued a $204.00 price objective (up from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th. Citigroup reaffirmed a “neutral” rating and issued a $204.00 price target (up previously from $195.00) on shares of Krystal Biotech in a research note on Tuesday. Chardan Capital increased their price objective on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research note on Monday, August 5th. Finally, HC Wainwright restated a “buy” rating and issued a $200.00 target price on shares of Krystal Biotech in a research report on Monday, August 5th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $185.63.

Krystal Biotech Stock Performance

Shares of NASDAQ KRYS traded up $1.80 during midday trading on Thursday, reaching $182.17. The company’s stock had a trading volume of 144,558 shares, compared to its average volume of 379,286. The company has a market cap of $5.20 billion, a P/E ratio of 97.42 and a beta of 0.84. The business’s 50 day moving average price is $186.63 and its two-hundred day moving average price is $164.72. Krystal Biotech has a fifty-two week low of $93.95 and a fifty-two week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, August 5th. The company reported $0.53 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.03. The business had revenue of $70.28 million during the quarter, compared to analyst estimates of $65.27 million. Krystal Biotech’s revenue for the quarter was up 70283900.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.25) EPS.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Jamison Private Wealth Management Inc. acquired a new stake in shares of Krystal Biotech in the second quarter valued at about $28,000. GAMMA Investing LLC increased its position in Krystal Biotech by 160.3% during the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after purchasing an additional 93 shares during the period. Key Financial Inc acquired a new stake in Krystal Biotech during the 2nd quarter valued at approximately $28,000. Blue Trust Inc. raised its holdings in Krystal Biotech by 2,328.6% during the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after purchasing an additional 163 shares during the last quarter. Finally, Quest Partners LLC acquired a new position in shares of Krystal Biotech in the 2nd quarter worth approximately $71,000. 86.29% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total value of $4,394,000.00. Following the completion of the transaction, the insider now directly owns 1,525,882 shares in the company, valued at approximately $268,189,020.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Julian S. Gangolli sold 20,000 shares of the firm’s stock in a transaction on Monday, May 20th. The shares were sold at an average price of $164.13, for a total transaction of $3,282,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the completion of the sale, the insider now directly owns 1,525,882 shares in the company, valued at approximately $268,189,020.32. The disclosure for this sale can be found here. Insiders own 14.10% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).